Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128332 | 1.00 | TSHR (0.44) | TSHRSMN1; SMN2HPGDRECQLMEN1 | |
| SCHEMBL3673890 | 0.85 | TSHR (0.50) | TSHRSMN1; SMN2HPGDRECQLMEN1 | |
| SCHEMBL3673892 | 0.85 | TSHR (0.50) | TSHRSMN1; SMN2HPGDRECQLMEN1 | |
| SCHEMBL28127289 | 0.85 | TSHR (0.50) | TSHRSMN1; SMN2HPGDRECQLMEN1 | |
| SCHEMBL19036963 | 0.83 | KDM4E (0.35) | TSHRSMN1; SMN2RECQLMEN1KMT2A | |
| SCHEMBL31308086 | 0.83 | TSHR (0.36) | TSHRSMN1; SMN2RECQLMEN1KMT2A | |
| SCHEMBL3397754 | 0.81 | SMN1; SMN2 (0.51) | TSHRSMN1; SMN2HPGDNPSR1ALDH1A1 | |
| SCHEMBL2294082 | 0.81 | SMN1; SMN2 (0.51) | TSHRSMN1; SMN2HPGDNPSR1ALDH1A1 | |
| SCHEMBL25646522 | 0.81 | TSHR (0.46) | TSHRSMN1; SMN2HPGDRECQLMEN1 | |
| SCHEMBL2294079 | 0.81 | SMN1; SMN2 (0.51) | TSHRSMN1; SMN2HPGDNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655330-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | Purdue Pharma LP (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8367680-B2 | Antibacterial small molecules and methods for their synthesis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2012085650-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20090270423-A1 | ANTIBACTERIAL SMALL MOLECULES AND METHODS FOR THEIR SYNTHESIS | NATIONAL SCIENCE FOUNDATION | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270423-A1 | ANTIBACTERIAL SMALL MOLECULES AND METHODS FOR THEIR SYNTHESIS | CLSPN, FDPS, DHPS | TSHR 4724/4885SMN1; SMN2 4722/4885HPGD 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.